Effect of MD1003 in Spinal Progressive Multiple Sclerosis

NCT02220933 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

144

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: MD1003 100mg capsule
DRUG: Placebo

Sponsor

MedDay Pharmaceuticals SA